AzTrials
AzTrials

Ischemic StrokeCORAISNCT00701818

Coronary Arteriosclerosis in Patients With Acute Ischemic Stroke

An observational study of Ischemic Stroke and Myocardial Ischemia, run by Vejle Hospital at 1 site in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The specific objectives of this thesis are in a cohort of patients with an acute ischemic stroke, 1. To establish the degree of coronary arteriosclerosis. 2. To describe left ventricular systolic and diastolic function in relation to changes of NT-proBNP. Read more about this study

Who is it for?
Ages 18 years and older
How many people
25 participants
Where
1 siteDenmark
Study dates
May 2008to May 2010
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The study is a prospective, consecutive study of patients primarily admitted to the Department of Neurology, Vejle Hospital with symptoms suggestive of an acute ischemic stroke according to the World Health Organization criteria

Who may be able to join

  • Age ≥ 18 years old
  • Symptoms suggestive of an acute ischemic stroke
  • Informed consent

Who cannot join

  • Present intracerebral or subarachnoid haemorrhage
  • Present intracerebral vascular malformation
  • Present transient ischemic attack
  • Prior coronary bypass surgery or percutaneous coronary intervention
  • Pacemaker
  • Allergy to contrast
  • Lack of cooperation

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Department of Cardiology, Vejle Hospital

    Vejle, 7100

Other trials in Denmark

About this study

Official title: Coronary Arteriosclerosis in Patients With Acute Ischemic Stroke Prevalence and Characteristics as Measured by CT Angiography, Echocardiography and Biomarkers

The specific objectives of this thesis are in a cohort of patients with an acute ischemic stroke,

  1. To establish the degree of coronary arteriosclerosis.
  2. To describe left ventricular systolic and diastolic function in relation to changes of NT-proBNP.
Read the detailed description

Background:

Stroke and myocardial infarction are leading causes of death and disability in the industrialized countries. Multiple interactions exist between the various forms of cardiovascular and cerebrovascular diseases and several risk factors for the development of stroke and major cardiovascular diseases are similar, as emphasized by the recent publication of a common set of guidelines for the primary prevention of both. Following myocardial infarction the stroke incidence is markedly increased, particular early after myocardial infarction. Additionally, non-stroke cardiovascular disease, especially coronary artery disease, is the main cause of long-term mortality in patients surviving cerebrovascular diseases. The history of ischemic heart disease in stroke patients is often unreliable because of cognitive and language impairments or simply because ischemic heart disease is asymptomatic. For at least 25 years myocardial damage has repeatedly been proposed as a consequence of an acute stroke, i.e. being neuromediated. Most prior studies were performed in patients with subarachnoid hemorrhage, and consequently only limited data regarding ischemic stroke, the most common cerebrovascular ailment, are available. Recently it has been demonstrated that highly sensitive and specific markers for the detection of myocardial necrosis, i.e., cardiac troponins, may be elevated in 0 % - 34 % of patients with ischemic stroke. However, the majority of the studies conducted have not sufficiently evaluated coexisting coronary artery disease. The neuromediated theory has been supported in patients with subarachnoid hemorrhage and elevated troponin levels due to lack of significant obstructive coronary artery disease evaluated by coronary angiograms. Little is known about a conceivable cause-effect relationship between acute ischemic stroke and myocardial necrosis, i.e., neuromediation, or if the elevated levels of troponin are caused by direct cardiac damage, i.e., AMI.

Recently, several reports have demonstrated that levels of natriuretic peptides are increased in patients with acute ischemic stroke. The hormone Brain Natriuretic Peptide (BNP) and its split product (NT-proBNP) derives predominantly from the myocardium and is processed as a response to stretch of cardiomyocytes and hemodynamic stress. The mechanism of elevated levels of NT-proBNP in the setting of acute ischemic stroke is unknown. Myocardial ischemia is known to cause release of NT-proBNP. Accordingly, levels of NT-proBNP are higher in acute ischemic stroke patients with ST-segment depression on 12-lead ECG than in those without. However, it is unknown whether levels of NT-proBNP are correlated to coronary arteriosclerosis and left ventricle function in patients with acute ischemic stroke.

The current gold standard for the detection of atherosclerotic coronary artery disease (CAD), invasive coronary angiography (CAG), allows direct visualization of the coronary artery lumen. Inconvenience to patients and a small but not negligible risk of complications related to CAG have prompted an intensive search for alternative, reliable non-invasive means of coronary artery visualisation. Standard non-invasive methods such as stress testing lack sufficient sensitivity in detecting significant CAD. Over the last decade multislice computed tomography (MSCT) has emerged as a promising non-invasive method in the assessment of CAD. Previous studies have convincingly demonstrated a very high negative predictive value of MSCT coronary angiography (CTA) with CAG as the reference. Thus, a normal CTA seems to allow the clinician to rule out the presence of hemodynamic relevant coronary artery stenoses with a high degree of reliability. In addition to detecting significant coronary artery stenosis, recent focus has been on visualising and characterising coronary artery plaques. Both necropsy and coronary intravascular ultrasound (IVUS) studies have shown that "normal" vessels at CAG may in fact contain a significant amount of atherosclerotic plaques. Independent of the degree of coronary artery stenosis, some plaques may be at increased risk of erosion or rupture. The latter, unstable plaques are thought to trigger acute coronary ischemic events. Accordingly, the release of troponins, NT-proBNP and ECG changes observed in these patients could be due to CAD. So far serial investigation of CAD has never been performed in patients with acute ischemic stroke.

Objective:

The specific objectives of this thesis are in a cohort of patients with an acute ischemic stroke,

  1. To establish the degree of coronary arteriosclerosis.
  2. To describe left ventricular systolic and diastolic function in relation to changes of NT-proBNP.

Inclusion Criteria:

  1. Age ≥ 18 years old
  2. Symptoms suggestive of an acute ischemic stroke
  3. Informed consent

Exclusion Criteria:

  1. Present intracerebral or subarachnoid haemorrhage
  2. Present intracerebral vascular malformation
  3. Present transient ischemic attack
  4. Prior coronary bypass surgery or percutaneous coronary intervention
  5. Pacemaker
  6. Allergy to contrast
  7. Lack of cooperation

Clinical evaluation:

All patients included in the study will have a computed tomography scan performed at the time of admission. The patients included undergo a baseline clinical evaluation, a structured interview and examination of medical records focusing at

  • Hypertension
  • Dyslipidemia
  • Diabetes mellitus
  • Smoking
  • Alcohol consumption
  • Medication
  • Atrial fibrillation
  • Ischemic heart disease
  • Angina Pectoris (CCS classification)
  • Heart failure (NYHA- and KILLIP-classification)
  • Peripheral Arterial Occlusive Disease

Electrocardiography:

A 12-lead resting ECG is obtained immediately on admission and up to each of the following five days in the morning. The 12-lead resting ECGs were recorded in the supine position with a paper speed of 25 mm/s. All ECGs are interpreted by two experienced cardiologist under blinded conditions. The ECG findings of interest in this thesis are horizontal or downsloping ST-segment depression ≥0.1 mV, T-wave inversion ≥0.1 mV in two or more contiguous leads, and ST-segment elevation ≥0.2 mV in leads V1-3; ST-elevation ≥0.1 mV in other leads.

Holter monitoring:

Holter 24-hour ECG recordings are performed with Reynolds Medical Tracker 3 and a Pathfinder 700 (Reynolds Medical Limited, England) for analysis. An ischemic episode is defined as ≥0.1 mV of horizontal or downsloping ST-segment depression compared to baseline, measured 80 ms after the J-point. An episode of ST-segment depression has to last ≥2 minutes in order to count and two episodes have to be separated by at least two minutes. In patients with resting ST-segment depression additional ≥0.1 mV ST-segment depression has to be present. Every episode of ST-segment deviation is verified by ECG printouts (25 mm/s). Furthermore, Holter monitoring will be analyzed for occurrence of atrial arrhythmias. Evaluation of ischemic and arrhythmias episodes is interpreted visually by two cardiologist blinded to other patient characteristics.

Blood Sampling:

Blood samples are drawn immediately on admission and up to each of the following five days in the morning. Specimens for NT-proBNP, troponin T and I, CK-MB, myeloperoxidase, oxidated low-density lipoprotein, osteoprotegerin are collected. All analyses are performed at the Department of Clinical Biochemistry, Vejle Hospital.

Echocardiography:

Doppler echocardiography will be performed as soon as the patient condition allows. Examinations will be performed on a GE medical Vivid 7 ultrasound machine. Images will be obtained from the parasternal and apical windows. M-mode recordings will be done in the parasternal long-axis view. Pulsed Doppler measurements of mitral inflow will be obtained with the transducer in the apical four-chamber view, with a 1-2 mm Doppler sample volume placed between the tips of mitral leaflets during diastole. Tissue Doppler imaging of the mitral annulus will be obtained from the apical 4-chamber view with a 1.5-mm sample volume placed at the medial mitral annulus. All Doppler echocardiographic examinations are done with horizontal sweep set to 100 mm/s. At least 3-5 cardiac cycles will be measured. Finally color coded real time tissue Doppler images will be acquired in the apical windows.

  • End-systolic, end-diastolic volume and ejection fraction will be calculated according to the Simpson modified biplane method.
  • LV mass will be estimated using the recommendations of the American Society of Echocardiography.
  • Maximal left atrial volume will be measured at end-systole with the use of two orthogonal apical views.
  • From the pulsed wave mitral inflow signal, peak E wave velocity, peak A wave velocity, and mitral E-wave deceleration time will be measured. From pulsed wave Doppler recording of LV outflow ejection time will be recorded. From these recordings Tei index will be assessed.
  • From peak tricuspid regurgitant velocity and size of inferior v. cava pulmonary arterial systolic pressure will be estimated.
  • From the tissue Doppler assessment of the medial mitral annulus early (E') diastolic velocity will be recorded. Diastolic function will be graded in grades 0-3 and diastolic E/e' ratio calculated.
  • From color coded tissue Doppler images systolic longitudinal fibre shortening will be assessed using tissue tracking, and systolic strain will be assessed on a regional basis.

Multislice computed tomography coronary angiography:

Examinations are performed at the Department of Cardiology, Vejle Hospital with dual source CT (DSCT) scanner technology (Siemens Definition; Forcheim, Germany). Tube voltage is 120kV for both tubes, current 560 mA with modulation and full current between 25 % - 80 % of the RR interval. Gantry rotation time is 330 msec, pitch is 0.20-0.44 according to the heart rate. Per rotation 64 slices are generated with a collimation of 0.6 mm resulting in an isotropic voxel size of approximately 0.6 mm. A bodyweight adapted volume of contrast agent (Iomeron 350) is injected continuously at rate of 5 ml /sec. The scan is initiated according to a bolus tracking protocol (aortic root attenuation level of 100 HU). Axial images are reconstructed with 0.75 mm slice thickness, and a 0.5 mm increment using a medium sharp kernel (B26) and retrospective ECG gating. The reconstructions are performed in 5 % steps over the relevant part of the RR cycle using a single-segment algorithm. In case of atrial fibrillation, data sets were reconstructed in 50 ms steps. Using a semi-automated Hounsfield dependent algorithm, differentiation between contrast enhanced lumen, vessel wall and atherosclerotic plaques, is performed. Atherosclerotic plaques will be categorized into calcified (>130 HU, high density plaque), non-calcified (< 60 HU, low density plaque), and mixed-type plaques (60-130 HU, intermediate density plaque), respectively. According to an American Heart Association 17 segmental coronary artery model, stenoses > 50 % or > 75 % are registered. Main coronary vessels (left main, left anterior descending artery, circumflex, and the right coronary artery) and side branches with a lumen diameter > 1, 5 mm are analysed. Image quality will be assessed as good (no artefacts related to motion, calcification or noise), satisfactory (artefacts present, but assessment of artery stenosis possible), or unsatisfactory (artefacts compromising the evaluation of artery stenosis). Images are analysed by two independent observes without knowledge of the patient history.

Medical subject headings
Ischemic Stroke, Myocardial Ischemia, Coronary Artery Disease

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Jun 2008 (estimated)
  2. Study startMay 2008
  3. Primary completionMay 2010
  4. Study completionMay 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
25 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00701818
Sponsor's protocol ID
S-20070097
Acronym
CORAIS
Status last verified
Jun 2015
First submitted
18 Jun 2008
Last updated
3 Jun 2015
Results posted
No
Data monitoring committee
No

Publications

  • Goldstein DS. The electrocardiogram in stroke: relationship to pathophysiological type and comparison with prior tracings. Stroke. 1979 May-Jun;10(3):253-9. doi: 10.1161/01.str.10.3.253.

    PubMed 462510
  • Lindgren A, Wohlfart B, Pahlm O, Johansson BB. Electrocardiographic changes in stroke patients without primary heart disease. Clin Physiol. 1994 Mar;14(2):223-31. doi: 10.1111/j.1475-097x.1994.tb00508.x.

    PubMed 8205753
  • Dimant J, Grob D. Electrocardiographic changes and myocardial damage in patients with acute cerebrovascular accidents. Stroke. 1977 Jul-Aug;8(4):448-55. doi: 10.1161/01.str.8.4.448.

    PubMed 898240
  • Khechinashvili G, Asplund K. Electrocardiographic changes in patients with acute stroke: a systematic review. Cerebrovasc Dis. 2002;14(2):67-76. doi: 10.1159/000064733.

    PubMed 12187009
  • Barber M, Morton JJ, Macfarlane PW, Barlow N, Roditi G, Stott DJ. Elevated troponin levels are associated with sympathoadrenal activation in acute ischaemic stroke. Cerebrovasc Dis. 2007;23(4):260-6. doi: 10.1159/000098325. Epub 2006 Dec 29.

    PubMed 17199083
  • Jensen JK, Atar D, Mickley H. Mechanism of troponin elevations in patients with acute ischemic stroke. Am J Cardiol. 2007 Mar 15;99(6):867-70. doi: 10.1016/j.amjcard.2006.10.052. Epub 2007 Feb 2.

    PubMed 17350385
  • Jensen JK, Kristensen SR, Bak S, Atar D, Hoilund-Carlsen PF, Mickley H. Frequency and significance of troponin T elevation in acute ischemic stroke. Am J Cardiol. 2007 Jan 1;99(1):108-12. doi: 10.1016/j.amjcard.2006.07.071. Epub 2006 Nov 9.

    PubMed 17196472
  • Fure B, Bruun Wyller T, Thommessen B. Electrocardiographic and troponin T changes in acute ischaemic stroke. J Intern Med. 2006 Jun;259(6):592-7. doi: 10.1111/j.1365-2796.2006.01639.x.

    PubMed 16704560
  • Etgen T, Baum H, Sander K, Sander D. Cardiac troponins and N-terminal pro-brain natriuretic peptide in acute ischemic stroke do not relate to clinical prognosis. Stroke. 2005 Feb;36(2):270-5. doi: 10.1161/01.STR.0000151364.19066.a1. Epub 2004 Dec 16.

    PubMed 15604421
  • Jensen JK, Mickley H, Bak S, Korsholm L, Kristensen SR. Serial measurements of N-terminal pro-brain natriuretic peptide after acute ischemic stroke. Cerebrovasc Dis. 2006;22(5-6):439-44. doi: 10.1159/000094997. Epub 2006 Aug 11.

    PubMed 16912478
  • Iltumur K, Yavavli A, Apak I, Ariturk Z, Toprak N. Elevated plasma N-terminal pro-brain natriuretic peptide levels in acute ischemic stroke. Am Heart J. 2006 May;151(5):1115-22. doi: 10.1016/j.ahj.2005.05.022.

    PubMed 16644347
  • Jensen JK, Korsholm L, Hoilund-Carlsen PF, Atar D, Kristensen SR, Mickley H. The relation between electrocardiographic ST-T changes and NT-proBNP in patients with acute ischemic stroke. Scand Cardiovasc J. 2007 Oct;41(5):294-8. doi: 10.1080/14017430701601644.

    PubMed 17886116

Questions about this trial

What is this clinical trial studying?

An observational study of Ischemic Stroke and Myocardial Ischemia, run by Vejle Hospital at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Jun 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00701818, which also lists 12 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jun 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in